



Burden of HCV infection among pregnant women with assessment of risk factors and pregnancy outcome in HCV infected: A hospital based study from Uttarakhand

Authors

Purnima Upreti¹, Rajesh Kumar Singh², Vandna Arya³

¹Assistant Professor, Dept of Obstetrics and Gynaecology, Govt Medical College, Haldwani, Nainital-263139

Email: purnima_upreti@yahoo.com, Mobile No: 08979977210

²Associate Professor, Dept of Community Medicine, Govt Medical College, Haldwani, Nainital-263139

³Junior Resident, Dept of Obstetrics and Gynaecology, Govt Medical College, Haldwani, Nainital-263139
Mobile No. 08868092960

Abstract

Introduction: Hepatitis-C is a global health problem. Risk factors for HCV infection include intravenous drug use, transfusion of infected blood or blood products, unsafe therapeutic injections and surgical, dental procedures with improperly sterilized instruments. With rising incidence of HCV infection, a significant number of pregnant women are getting affected. However, there is little research regarding the burden and impact of HCV infection on pregnancy.

Aim and Objectives: The aim of the study was to evaluate burden and impact of HCV infection among pregnant women in a tertiary care centre of Uttarakhand. The objectives were to find out seroprevalence of Hepatitis-C among pregnant women, study the socio-demographic profile and risk factor profile of anti HCV positive pregnant women, to study the pregnancy outcome in anti HCV pregnant women and evaluate the need for universal antenatal screening for HCV infection.

Material and Methods: A retrospective hospital record based study of all pregnant women delivered in Dr. Sushila Tiwari Government Hospital, Haldwani between January 2014 and December 2015 was carried out. All the pregnant women coming to the hospital are routinely screened for HCV infection as per standard protocol of the hospital. HCV status of all delivered patients was studied. A predesigned semi-structured proforma was used for collecting information regarding socio-demographic variables, risk factors and pregnancy outcome among anti-HCV positive women. Data collected was entered in MS excel and analyzed using Epi-info.

Result: Seroprevalence of Hepatitis-C among pregnant women was 0.89% in our study. Among the risk factors studied, previous surgery and blood transfusion were found to be the important risk factors observed in 16 (25.80%) and 5 (8.06%) of anti-HCV positive pregnant women. About 42 % of women had no identifiable risk factors. Pre term delivery was found to be the most common complication (33.8%) among the anti-HCV positive women. This was followed by Fetal Distress (14.51%), Pregnancy Induced Hypertension (P.I.H.), Ante- Partum Haemorrhage (A.P.H.) and Intra Uterine Fetal Death (11.29% each). About one-third of neonates (33.87%) born to anti-HCV positive mothers were premature at birth.

and 37.09% of neonates had low birth weight.

Conclusion: Incidence of HCV infection is on the rise. HCV infection in pregnant women is associated with several adverse maternal and neonatal outcomes. Universal screening of all pregnant women should be done for HCV infection as at risk screening may miss significant proportion of pregnant women with HCV infection.

Keywords: Hepatitis C virus, Seroprevalence, Risk Factors, Pregnancy Outcome.

INTRODUCTION

Hepatitis-C is a global health problem affecting 2-3% of world population. ⁽¹⁾ Population based studies on prevalence of HCV infection in India are scarce. Blood bank data is the largest source of data on prevalence of HCV infection in India. Based on these data, prevalence of HCV infection in India has been variously estimated as 0.9 to 1.9%. ^(2,3) Prevalence of HCV among pregnant women ranges from 0.14 to 4.4% in developed countries ^(4,5) and from 0.6 to 1.4% in India ⁽⁶⁻⁸⁾. Risk factors for HCV infection include intravenous drug use, transfusion of infected blood or blood products, unsafe therapeutic injections, sexual transmission, occupational (needle – stick) injuries or nosocomial transmission during healthcare related procedures such as surgery, haemodialysis and organ transplantation ⁽¹³⁾.

However, in 40% of cases, there are no identifiable risk factors. ⁽⁹⁾ Approximately 7-8% of anti-HCV positive pregnant women can transmit hepatitis-C virus to their offspring. ⁽¹⁰⁾ With rising incidence of HCV infection, a significant number of pregnant women are getting affected. However, there is little research regarding the impact of HCV on pregnancy outcome.

Though studies regarding seroprevalence patterns of HCV among blood donors have been undertaken in Uttarakhand in the past where seroprevalence was found to be 0.64% in Kumaon region ⁽¹¹⁾ and 0.20% in Garhwal region ⁽¹²⁾, but those on the estimates of seroprevalence patterns and risk factors among pregnant women and impact of HCV infection on pregnancy outcome are yet to be done in Uttarakhand. Therefore, this hospital based study was aimed to evaluate the burden and impact of HCV infection among pregnant women admitted for delivery in the department of Obstetrics and Gynaecology of Dr.

Sushila Tiwari Government hospital and Government Medical College, Haldwani. The objectives were to find out seroprevalence of Hepatitis-C among pregnant women, study the socio-demographic profile and risk factor profile of anti HCV positive pregnant women, to study the pregnancy outcome in anti-HCV pregnant women and evaluate the need for universal antenatal screening for HCV.

MATERIAL AND METHODS

A retrospective hospital record based study of all pregnant women delivered in the department of Obstetrics and Gynaecology of Dr. Sushila Tiwari Government Hospital and Government Medical College, Haldwani between January 2014 and December 2015 was carried out. The hospital is a tertiary care centre situated in block Haldwani of district Nainital of Uttarakhand. It provides antenatal and specialized obstetrics services to the population of the Kumaon region of Uttarakhand and neighbouring districts of Uttar Pradesh. All the pregnant women coming to the hospital are routinely screened for HCV as per standard protocol of the hospital. HCV status of all women delivered during the above mentioned period was studied. A predesigned semi-structured proforma was used for collecting information regarding socio-demographic variables, risk factors and pregnancy outcome among anti-HCV positive women. Ethical approval for the study was taken from institution ethical committee.

Data collected was entered in MS excel and analyzed using SPSS version 16.

RESULTS

Table 1 Distribution of anti-HCV positive women according to socio-demographic variables (n=62)

Socio-demographic variables	No.	%
AGE (Years)		
15 – 20	10	16.1
21 – 25	28	45.2
26 – 30	18	29.0
31 – 35	05	08.1
> 35	01	01.6
Mean (SD)	25.18 (4.29)	
PARITY		
Primipara	27	43.5
Multipara	35	56.5
RELIGION		
Hindu	32	51.6
Muslim	22	35.5
Sikh	08	12.9
RESIDENCE		
Rural	35	56.46
Urban	27	43.54
DISTRICT		
Udham Singh Nagar (Uttarakhand)	44	70.96
Rampur (Uttar Pradesh)	13	20.96
Nainital (Uttarakhand)	04	06.45
Bijnor (Uttarakhand)	01	01.61

Table 2: Distribution of risk factors among anti-HCV positive pregnant women (n=62)

Risk factors	No.	%
Previous major surgery	16	25.80
Previous abortion	08	12.90
Previous Dilatation and Evacuation	07	11.29
Previous Blood Transfusion	05	08.06
None	26	41.93

Table 3: Maternal and neonatal outcomes among anti-HCV positive women (n=62)

Maternal outcome	No.	%
Pregnancy Complications		
Pregnancy Induced Hypertension (PIH)	07	11.29
Ante-Partum Haemorrhage (APH)	07	11.29
Anaemia	06	09.67
Oligohydramnios	05	08.05
Premature Rupture of Membranes (P.R.O.M.)	04	06.45
Preterm Labour	21	33.87
Fetal Distress	09	14.51
Intra Uterine Fetal Death (I.U.F.D.)	07	11.29
Mode of delivery		
Caesarean Section	39	62.9
Vaginal Delivery	23	37.1
Neonatal Outcome		
Prematurity	21	33.87
Low Birth Weight(<2.5 Kg)	23	37.09

Out of 6934 pregnant women who delivered during the study period, 62 tested positive for Hepatitis-C virus infection. Seroprevalence of Hepatitis-C among pregnant women was 0.89% in our study.

Mean age of anti-HCV positive women was 25.18 years. Majority of these women (45.2%) were in the age group of 21-25 years. Among anti-HCV positive women, 27 (43.5%) were primipara and 35 (56.5%) were multipara. 32 (51.6%) were Hindu, 22 (35.5%) were Muslim and 8 (12.9%) were Sikh. Of 62 HCV positive women 35 (56.46%) were from rural area and 27(43.54%) from urban area. Majority 44 (70.96%) of the anti-HCV positive women belonged to district Udham Singh Nagar and only 4(6.45%) belonged to district Nainital of Uttarakhand. (Table 1)

Among the known risk factors for transmission of HCV infection, 16 (25.8%) women had history of major surgery before the index pregnancy, 8 (12.9%) had history of previous abortion, 7 (11.2%) underwent Dilatation and Evacuation, 5(8.1%) received blood transfusion before the index pregnancy. None of the Anti-HCV positive women had history of Intra Venous Drug Abuse. About 42% of anti-HCV positive women had no identifiable risk factors. (Table 2)

Out of 62 HCV reactive women, 39 (62.9%) delivered by caesarean section and 23(37.1%) by vaginal route. (Table 3)

In our study, pre-term labour resulting into pre-term birth was found to be the most common complication (33.87%) among the anti-HCV positive pregnant women. This was followed by Fetal Distress (14.51%), Pregnancy Induced Hypertension (P.I.H.), Ante- Partum Haemorrhage (A.P.H.) and Intra Uterine Fetal Death (11.29% each). Other pregnancy complications were anaemia (9.67%) Oligohydramnios (8.05%) and Premature Rupture Of Membranes(P.R.O.M.) (6.45%) (Table 3)

About one -third of neonates (33.87%) born to anti-HCV positive mothers were premature at birth and 37.09% neonates had low birth weight (Table 3)

DISCUSSION

The seroprevalence of Hepatitis-C among pregnant women was 0.89% in our study which is comparable to the seroprevalence reported by Ashok et al (1.03%)⁽⁷⁾ and Rudraparthy et al (0.6%)⁽⁶⁾, but very low as compared to that reported by Farhana s. et al (3.44%)⁽¹³⁾ and Goyal L.D. et al (2.8%)⁽¹⁴⁾. The estimated seroprevalence of HCV antibodies among pregnant women in India has ranged from 0.6 to 1.4%⁽⁶⁻⁸⁾

In our study, maximum number of anti-HCV positive women (45%) were in the 21-25 years age group which is similar to the findings of Goyal L.D.et al (45%)⁽¹⁴⁾, Rudrapathy et al (52%)⁽⁶⁾, Farhana et al (49%)⁽¹³⁾ and Ashok et al (51.2%)⁽⁷⁾ In our study, the seroprevalence was found to be higher upto the age of 25 years and decreased after that. Our finding is similar to the findings of Ashok et al⁽⁷⁾ and Goyal L.D. et al⁽¹⁴⁾. The highest prevalence of HCV infection occurs among individuals of reproductive age group^(16,17). Seropositivity has been found to increase upto the age of forty years and then decreases overtime.⁽¹⁸⁾, this can be explained by the greater probability of exposure of these women to the risk factors for HCV infection.

Most of the Anti-HCV positive women (56.5%) in our study were multipara. Farhana et al⁽¹³⁾, Ashok et al⁽⁷⁾ and Goyal L.D⁽¹⁴⁾ also reported higher seroprevalence among multipara. The multipara might be at a higher risk because of their past pregnancies, obstetric procedures and previous blood transfusion.

The present study found that more than half (56%) of the anti-HCV positive pregnant women were residing in rural areas. Goyal.L.D.et al⁽¹⁴⁾ also found higher infection rates among rural residents. In our study, majority of anti-HCV positive pregnant women were from district Udham Singh Nagar (70.96%), and only 6.45% were from district Nainital. Our finding is consistent with the finding of Rawat v. et al⁽¹²⁾ who also reported higher HCV prevalence (3.25%) among blood donors from district Udham Singh Nagar, whereas

HCV prevalence among blood donors from district Nainital was only 0.23%.

Parenteral transmission is the most important route of transmission of HCV infection. Intravenous drug use is the predominant mode of transmission of HCV in several developed countries, however in developing countries, the main modes of transmission are transfusion of infected blood and its components and surgical, dental procedures with improperly sterilized instruments and unsafe therapeutic injections with reused syringes. 38% of HCV infection in India may be attributable to unsafe therapeutic injections⁽¹⁹⁾

In our study, past history of surgical procedures was found in majority of patients which is consistent with the findings of a study from Pakistan in which previous vaginal deliveries with episiotomy, previous surgeries, previous blood transfusion and Previous Dilatation and Curettage for abortion or Dysfunctional Uterine Bleeding were taken as independent variables, Only past history of surgical procedures was found to be the most important risk factor for transmission of H.C.V⁽²⁰⁾

In present study, previous blood transfusion as important risk factor for transmission of HCV infection was observed in 8% of patients. Blood transfusion is also reported to be a major source of HCV infection in a study from Hazra, Pakistan⁽²¹⁾ Our study showed that about 42 % of anti-HCV positive women had no identifiable risk factors for HCV infection. This compares well with the observation that 40-73% of HCV positive women had no obvious risk factors for HCV infection.^(9, 22,23,24)

Our study demonstrates that HCV infection in pregnant women is associated with several adverse maternal and neonatal outcomes. We found that about one-third pregnant women with HCV infection had pre-term labor. Studies evaluating prematurity with maternal HCV infection have contradictory results. A study from Canada found high rate of pre-term labor among anti-HCV positive pregnant women⁽²⁵⁾. Some

other studies also found higher rates of pre-term labor among HCV infected women. ^(26, 27,28,29,30, 31)

Two studies found no difference among HCV reactive women. ^(20, 32)

In our study, Premature Rupture of Membranes (PROM) was found in 6% of women. In one study, viraemia in anti-HCV positive mother was associated with Premature Rupture of Membranes. ⁽³³⁾

In present study 11.29% of anti-HCV positive women had pregnancy induced hypertension and antepartum haemorrhage. Our findings are consistent with the findings of Goyal L.D.et al ⁽¹⁴⁾ Latt et al also found higher rate of pregnancy induced hypertension among HCV RNA positive women. ⁽³³⁾ .In a study Reddick et al found no association between HCV infection and pre-eclampsia, but the same study showed that individuals with Hepatitis-B and Hepatitis-C co-infection had increased risk for Antepartum haemorrhage. ⁽³⁰⁾

The present study reports intra uterine fetal death in 11% anti-HCV positive women. This finding is similar to the finding of a study from British Columbia ⁽²⁵⁾

Because HCV infection can cause vasculitis, involvement of placental vasculature can lead to vascular compromise of placenta ^(34,35) which can explain poor neonatal outcome ranging from low birth weight, intra uterine growth restriction, birth asphyxia to stillbirth..There is paucity of data on neonatal adverse outcome associated with maternal HCV infection. Some of the studies quote similar neonatal outcome in HCV reactive and non-reactive mothers ^(36,37) . In present study, about 34% of neonates born to anti-HCV positive women were premature at birth and about 37% had low birth weight. Our finding is consistent with the findings of PergamS.A., WangC.C.etal ⁽²⁹⁾

Testing of at risk mothers for Hepatitis-C infection is advocated by both the Centres for Disease Control and Prevention ⁽¹⁶⁾ and American College of Obstetrics and Gynaecology⁽³⁸⁾. Routine HCV screening of all pregnant women is not considered cost effective. ⁽³⁹⁾ However ,at risk

screening guidelines may miss significant proportion of pregnant women with HCV infection because upto 40% of pregnant women with Hepatitis-C infection have no identifiable risk factors ⁽⁹⁾ Secondly at risk screening is dependent on the health care providers having knowledge of risk factors for HCV infection as well as on women fully disclosing risk factors, Furthermore, such risk factors are under ascertained by healthcare providers during pregnancy. ^(40,41) So at risk screening may be inadequate ⁽⁵⁾. Pregnancy provides an opportunity to identify early HCV infection because many who are found to be HCV positive are unaware of their serological status ⁽⁴²⁾

LIMITATIONS

The present study is a retrospective study based on the analysis of hospital data of anti-HCV positive pregnant women admitted in our hospital for delivery so information on some variables such as risk factors like tattooing, piercing of nose or ears, dental procedures, HCV status of spouse etc and neonatal outcomes other than prematurity and low birth weight could not be collected.

CONCLUSION

Incidence of HCV infection is on the rise. HCV infection in pregnant women is associated with several adverse maternal and neonatal outcomes. Pregnancy complications like Pre-term labour, Pregnancy Induced Hypertension, Antepartum Hemorrhage and intrauterine fetal death are common in anti- HCV positive pregnant women. Prematurity and low birth weights are the common adverse outcomes among the neonates born to anti-HCV positive women. Universal screening of all pregnant women should be done for HCV infection as at risk screening may miss significant proportion of pregnant women with HCV infection.

REFERENCES

1. Baldo V, Baldovin T, Trivello R, et al. Epidemiology of HCV infection Curr Pharm Des. 2008;14:1646-54

2. Mukhopadhyaya A. HCV in India. J Biosci. 2008; 33:465–473. [PubMed]
3. Sievert W, Altraif I., Razavi H.A. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(suppl 2):61–80.[PubMed]
4. Ward C, Tudor-Williams G, Cotzias T, et al. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut. 2000;47(2):277–80
5. Silverman NS, Jenkin BK, Wu C, et al. Hepatitis C virus in pregnancy: seroprevalence and risk factors for infection. Am J Obstet Gynecol. 1993; 169:583–7.
6. Parthiban R., Shanmugam S., Velu V. et al. Transmission of hepatitis C virus from asymptomatic mother to child in southern India. Int J Infect Dis. 2009;13:e394–e400.[PubMed]
7. Kumar A., Sharma A., Gupta R.K., Kar P., Chakravarti A. Prevalence & risk factors for hepatitis C virus among pregnant women. Indian J Med Res.2007; 126:211–215. [PubMed]
8. Sood A., Midha V., Bansal M., Sood N., Puri S., Thara A. Perinatal transmission of hepatitis C virus in northern India. Indian J Gastroenterol. 2012;31:27–29.[PubMed]
9. Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) and rate of vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000; 31:751–5.
10. ACOG Educational Bulletin. Viral hepatitis in pregnancy. Number 248, July 1998. American college of obstetricians and gynecologists. Int J Gynaecol Obstet. 1998; 63:195–202.
11. Rawat, V.; Bhatt, U.; Singhai, M.; Kumar, A.; Malik, Y. P. S. Prevalence of hepatitis C virus infection among blood donors of Kumaon region of Uttarakhand Indian Journal of Medical Microbiology; Jul 2013, Vol. 31 Issue 3, p313
12. Bhawna Sethi, Satish Kumar, KS Butola, JP Mishra and Yogesh Kumar Seroprevalence pattern among blood donors in a tertiary health care center Internet Journal of Medical Update. 2014 Jan; 9(1):10-15
13. Shaikh, F., Syed Qaiser, H.N., Kousar, J., Allah Dino Memon, R. 2009. Prevalence and risk factors for hepatitis c virus during pregnancy. Gomal. J. Med. Sci., 2: 86- 88
14. Goyal Lajya Devi • Kaur Sharanjit • Jindal Neerja • Kaur Harpreet HCV and Pregnancy: Prevalence, Risk Factors, and Pregnancy Outcome in North Indian Population: A Case–Control Study. The Journal of Obstetrics and Gynecology of India. Oct 2014; 64(5)
15. Pankaj Puri, Anil C. Anand, Vivek A. Saraswat et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India J Clin Exp Hepatol. 2014 Jun; 4(2): 106–116.
16. Centers for Disease Control and Prevention, Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease. Morb Mortal Wkly Rep 1998; 47: 1-39.
17. Wasley AD, Alter MJ. Epidemiology of hepatitis C. Semin Liver Dis 2000; 20:1-16.
18. Stevens CE, Taylor PE, Pindych J, Choo QL, Bradley DW, Kuo G, et al. Epidemiology of hepatitis C virus: A preliminary study in voluntary blood donors. JAMA 1990; 263: 49-53.
19. Reid S. estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence. Indian J Community Med. 2012; 37:89–94. [PubMed]

20. Jaffery T, Tariq N, Ayub R, et al. Frequency of hepatitis C in pregnancy and pregnancy outcome. J Coll Physicians Surg Pak. 2005;15:716–79
21. Jadoon HA, Ahmed Z. Prevalence of anti-HCV in blood donors of hazara (NWFP) Pakistan. J Med Res 1999; 38: 7-9.
22. Ward C, Tudor-Williams G, Cotzias T, Hargreaves S, Regan L, Foster G R. Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing. Gut 2000;47 : 277-80
23. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002: June 10-12, 2002. Hepatology. 2002; 36(S1): S3–S20.
24. Zanetti AR, Tanzi E, Newell M-L. Mother-to-infant transmission of hepatitis C virus. J Hepatol 1999; 31 (Suppl 1) : 96-100
25. Deborah Money, MD, FRCSC, 1,2 Isabelle Boucoiran, MD, MSc, 1,2 Emily Wagner, MSc, 2 Simon Dobson, MD, MBBS, MRC, FRCPC, 3 Aaron Kennedy, MD, MSc, 1 Zoe Lohn, MSc, 2 Mel Krajden, MD, FRCPC, 4 Eric M. Yoshida, MD, FRCPC, MHSc 5 Obstetrical and Neonatal Outcomes Among Women Infected With Hepatitis C and Their Infants J Obstet Gynaecol Can 2014;36(9):785–794
26. Connell LE, Salihu HM, Salemi JL, August EM, Weldezelasse H, Mbah AK. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 2011; 31(8):1163–70
27. Berkley EM, Leslie KK, Arora S, Qualls C, Dunkelberg JC. Chronic hepatitis C in pregnancy. Obstet Gynecol 2008; 112(2 Pt 1):304–10.
28. Hillemanns P, Dannecker C, Kimmig R, Hasbargen U. Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy. Acta Obstet Gynecol Scand 2000; 79(7):543–7.
29. Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003–2005 Washington state birth cohort. Am J Obstet Gynecol 2008; 199(1):38.e1–38.e9.
30. Reddick KL, Jhaveri R, Gandhi M, James AH, Swamy GK. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat 2011; 18(7):e394–8.
31. Medhat A, el-Sharkawy MM, Shaaban MM, et al. Acute viral hepatitis in pregnancy. Int J Gynaecol Obstet 1993;40:25-31
32. Bohman VR, Stettler RW, Little BB, et al. Seroprevalence and risk factors for hepatitis C virus antibody in pregnant women. Obstet Gynecol 1992; 80:609-13.
33. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol 2000; 15:175-81.
34. Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. Am J Obstet Gynecol 2005; 192:452-7.
35. Sander CM, Gilliland D, Akers C, et al. Live births with placental hemorrhagic endovascularitis: Interlesional relationships and perinatal outcomes. Arch Pathol Lab Med 2002;126:157-64
36. Marti C, Pena JM, Bates I, et al. Obstetric and perinatal complications in HIV—infected women. Analysis of cohort of 167 pregnancies between 1997 and 2003. Acta Obstet Gynecol Scand. 2007;86(4):409–15
37. Jabeen T, Cannon B, Hogan J, et al. Pregnancy and pregnancy outcome in hepatitis C type 1b. QJM. 2000;93:597–601
38. American College of Obstetricians and Gynecologists. Primary and preventive care: Periodic assessments. ACOG technical bulletin no. 246. Washington (DC): American College of Obstetricians and Gynecologists; 2000. p. 1-7.

39. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: A cost-effectiveness analysis. Am J ObstetGynecol2005;192:1153-61
40. Boaz K, Fiore AE, Schrag SJ, et al. Screening and counseling practices reported by obstetrician-gynecologists for patients with hepatitis C virus infection. Infect Dis ObstetGynecol 2003; 11:39-44.
41. Giles ML, Sasadeusz JJ, Garland SM, et al. An audit of obstetricians' management of women potentially infected with blood-borne viruses. Med J Aust 2004;80:328-32
42. Floreani A, Paternoster D, Zappala F, et al. Hepatitis C virus infection in pregnancy. Br J ObstetGynaecol 1996;103:325-9.